Use of the CD2 signaling domain in second-generation chimeric antigen receptors
AssigneeThe Trustees of the University of Pennsylvania
InventorsCarl H. June, John Scholler, Avery D. Posey, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
Claims3
A cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), the CAR comprising an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the costimulatory signaling region comprises a CD2 signaling domain, wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.